Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/11/2025 ,inter alia, to consider and approve issuance of equity shares ....
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Smallcap 250 and 3.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eris Lifesciences has called a Board meeting on November 24, 2025 to consider issuing equity shares through a preferential issue on a non-cash basis. The proceeds (in share form) will go towards acquiring the remaining 30% stake in Swiss Parenterals Limited, which would make it a wholly-owned subsidiary. The issue will follow the Companies Act, 2013 and SEBI ICDR Regulations, and is subject to shareholder and other regulatory approvals. The Board may also convene an EGM or postal ballot to seek members' approval for the proposal.
Existing shareholders may see some dilution since the acquisition is being funded through a fresh equity issuance rather than cash. If completed, full ownership of Swiss Parenterals will give Eris tighter strategic control over the subsidiary, which investors should view as a consolidation move rather than a cash-out event.